Development of In Vitro Parkinson's Disease Model Mediated by MPP + and α‐Synuclein Using Wharton's Jelly Mesenchymal Stem Cells

Documenti analoghi

• SYNGR3 Accelerates α‐Synuclein Aggregation and Neurodegeneration in Parkinson's Disease
  di: Xin Wang, et al.
  Pubblicazione: (2026)
• Genetic Modification of Mesenchymal Stem Cell to Overexpress CXCR4 Enhances Treatment Efficacy for Brain Injury After Cardiopulmonary Resuscitation
  di: Yongfei Liu, et al.
  Pubblicazione: (2025)
• The Mechanism Underlying the Abnormal Expression of α‐Synuclein in the Cortical Lesions of Patients With FCD Type IIb and TSC
  di: Li Zhang, et al.
  Pubblicazione: (2026)
• Microglial Melatonin Receptor 1 Degrades Pathological Alpha‐Synuclein Through Activating LC3‐Associated Phagocytosis In Vitro
  di: Xiao‐Yu Yao, et al.
  Pubblicazione: (2024)
• Correction to “Microglial Melatonin Receptor 1 Degrades Pathological Alpha‐Synuclein Through Activating LC3 ‐Associated Phagocytosis In Vitro”
  Pubblicazione: (2025)